An Australian based Study on the Patterns of Short Acting Beta-2 Agonist (SABA) use and Its Potential Effects on Asthma Control (SABINA Australia)

Study identification

• EU PAS number:
  EUPAS105682
• Study ID:
  105683
• Official title and acronym:
  An Australian based Study on the Patterns of Short Acting Beta-2 Agonist (SABA) use and Its Potential Effects on Asthma Control (SABINA Australia)
• DARWIN EU® study:
  No
• Study countries:
  Australia
• Study description:
  An observational, cross-sectional study describing SABA prescribing, use and potential effects among asthma patients in Australia, using a unique platform of linked electronic healthcare records and patient questionnaires (OPCRDA).
• Study status:
  Ongoing

Research institutions and networks

Institutions

Optimum Patient Care Australia

Australia

Study timelines

Date when funding contract was signed

Planned: 25/11/2021

Actual: 25/11/2021

Study start date

Planned: 01/12/2021

Actual: 01/12/2021

Data analysis start date

Planned: 05/01/2022

Actual: 05/01/2022

Date of final study report

Planned: 01/12/2023

Sources of funding

Other

Pharmaceutical company and other private sector 

More details on funding

AstraZeneca Australia, Optimum Patient Care Australia

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable